RDF Media
BUY‘We’re making more programmes in more genres for more broadcasters than ever before’, commented David Frank, founder and chief executive of RDF Media, the acquisitive TV production play that floated on AIM in May 2005.
His words accompanied strong maiden full year figures to January from the fast growing content producer and rights distributor. Pre-tax profits (before float costs) beamed 26% higher to £5.3m on turnover raised 23.4% to £59.5m, driven by buoyant rights sales and acquisitions. Year-end cash was a reassuring £2.7m.
RDF continues to foster strong ties with the BBC, enjoying 209% growth in organic BBC revenues last year to £3.4m, with BBC sales including acquisitions an even higher £12.7m. The strength of the group’s relationship with Channel 4 was also in evidence with three new series commissioned – including Britain’s Top Dog and The Philanthropist – and the Wife Swap and Location Location Location brands reordered. Frank insists the rights division – which represented 3,010 of programme hours and made sales to 213 different broadcasters in every continent last year – continues to flourish in a rights market liberated in the wake of the Communications Act 2003.
The company has made four acquisitions since float, including IWC Media, which made RDF the biggest independent producer in Scotland (a savvy move given that broadcasters are under pressure to commission programming from outside London) and Presentable, which brought capacity in Wales as well as a foothold in the market for gaming-based programming.
For the current year, Investec Securities suggests pre-tax profits of £8m from a top line £92.8m, giving earnings of 14.2p and placing the shares on an undemanding forward multiple of 14.2. Buy.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £71.87m
PE Forecast: 14.2
Share price: 202p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
